Genetic variation influences adverse reaction to common antibiotic
Nature Genetics
June 1, 2009
A common genetic difference between people influences their chance of developing a rare but serious liver injury as a side effect of taking the antibiotic flucloxacillin, as reported in a paper published online in this week's issue of Nature Genetics.
Flucloxacillin is widely used in Europe and Australia to treat staphylococcus bacterial infections. In their study, Daly and colleagues found that individuals carrying the risk-associated gene variant were 80-100 times more likely than non-carriers to suffer liver injury in response to this antibiotic.
The risk-associated gene variant is relatively common in Northern Europe, but less prevalent in Africa and Asia. Despite being at substantially higher risk than non-carriers, only a small proportion of carriers actually develop liver problems in response to flucloxacillin. Thus, further tests will be needed to determine whether a genetic test would be clinically useful in guiding treatment options.
doi: 10.1038/ng.379
Research highlights
-
Dec 3
Ageing: Cellular rejuvenation restores vision in miceNature
-
Dec 1
Neurodegenerative disease: Two blood molecules may predict Alzheimer’s disease developmentNature Aging
-
Nov 27
Archaeology: Neanderthal thumbs better adapted to holding tools with handlesScientific Reports
-
Nov 26
Metabolism: Link between SARS-CoV-2 infection and cholesterol hints at COVID-19 treatment possibilitiesNature Metabolism
-
Nov 26
Evolution: Ancient bird sticks its big beak into the evolutionary recordNature
-
Nov 25
Stem cells: Modelling SARS-CoV-2 lung infection in a dishNature
